Generic semaglutide: what the FDA requires and why

Complete guide: GLP-1 drugs: a complete guide to semaglutide and beyond

What generic semaglutide is, and what it is not

Generic semaglutide is a version of brand semaglutide (Ozempic, Wegovy, Rybelsus) sold by a different manufacturer after the original product's patent and data protections lapse. A generic does not repeat the innovator's large clinical trials: it has to show that it is the same as the reference product in the active substance and that it behaves equivalently in the body. That is the regulatory contract, and it is what separates a generic from a "similar" product, a compounded preparation, or a powder that went through no review¹².

The distinction matters because the market uses the word "generic" loosely. An approved generic has a dossier a regulator reviewed, an inspected manufacturer and a traceable batch. A product sold as "semaglutide similar" may have none of that. In a drug class where WHO has already documented falsification in the regulated supply chain, the difference is clinical, not just commercial⁴. For background on the molecule, see our GLP-1 guide.

The molecule: an engineered peptide, not a natural one

Semaglutide is not natural GLP-1. It is an analogue designed at Novo Nordisk to resist degradation and act once a week, with sequence changes and a fatty-acid side chain that lets it bind albumin⁵. Its efficacy in obesity comes from manufacturer-funded trials: in STEP 1, 1,961 adults with overweight or obesity and no diabetes had a mean body-weight change of −14.9% at 68 weeks with semaglutide versus −2.4% with placebo (a difference of −12.4 percentage points)⁶. Cardiovascular outcomes trials were also published in type 2 diabetes (SUSTAIN-6) and in obesity without diabetes (SELECT)⁷⁸.

A 2026 narrative review describes semaglutide as a peptide made through a semi-recombinant process and notes that moving to chemical synthesis raises questions about regulatory pathways, manufacturing processes and clinical implications¹³. That sentence captures the technical debate over generics: the sequence can be identical, but the route to it leaves different fingerprints.

When generics arrive, and where

According to a Reuters report relayed by an intellectual-property firm in July 2025, a generic maker planned to launch its version of Wegovy in 87 countries in 2026, starting where the patent had already expired and "subject to patent expiry". Its chief executive said: "U.S. and Europe will open later… (and) all the other Western markets will be open between 2029 to 2033"³. The practical result is a split geography: some markets already have generic semaglutide and others will not for years.

The closest precedent is liraglutide. On December 23, 2024 the FDA approved the first generic referencing Victoza and stated that "liraglutide injection and certain other GLP-1 medications are currently in shortage" and that the agency "prioritizes assessment of generic drug applications for drugs in shortage"². The generic's labeling carries the same Boxed Warning about thyroid C-cell tumors as the brand².

What the FDA requires: sameness and impurities

On July 28, 2026 the FDA published 17 revised draft product-specific guidances for peptides, including "Semaglutide (OZEMPIC, NDA 209637)" and "Semaglutide (WEGOVY, NDA 215256)". It also said it is withdrawing its May 2021 guidance on ANDAs for highly purified synthetic peptides that refer to rDNA-origin listed drugs, because it "no longer reflects FDA's current scientific thinking". The new drafts, still open to public comment, cover five areas: submission of recombinant, synthetic or semi-synthetic peptides; innate immune response testing; impurity thresholds; higher-order structure assessment; and biological activity assessment¹.

The underlying logic was already in the earlier guidance. Once the active ingredient of the generic is shown to be the same as the reference drug's, the developer must mitigate residual immunogenicity risk by characterizing, with in silico and in vitro tools, differences in product- and process-related impurities. The specific worry is that a sequence modification creates new T-cell epitopes, so any new impurity above a threshold has to be evaluated with orthogonal methods that measure HLA binding and the capacity to elicit a T-cell response¹⁰.

Why impurities matter: immunogenicity in clinical terms

A peptide-related impurity is a molecule nearly identical to the intended one, for instance with an amino acid omitted, duplicated or modified, that appears during synthesis or storage. For a drug used for years, the theoretical risk is that the immune system recognizes that variant and makes antibodies. The 2024 FDA-CRCG workshop brought together the FDA, industry and academia precisely to discuss how to assess that risk for generic peptides and oligonucleotides⁹.

A case study on generic teriparatide shows the method: three in silico tools (EpiMatrix, ClustiMer, JanusMatrix), an in vitro HLA-DR binding test and a peripheral-blood mononuclear-cell T-cell assay. The authors found several impurities more immunogenic than teriparatide itself, along with a potentially tolerogenic sequence in the parent molecule¹⁰. It is worth noting that the authors are from EpiVax, a company that sells those tools, which they disclose as a conflict of interest¹⁰¹².

For liraglutide, a 2025 study compared synthetic (generic) with recombinant (brand) liraglutide in a mononuclear-cell assay and found no statistically significant difference in innate immunogenicity¹¹. That is reassuring, but it comes from a synthetic-peptide manufacturer and tested one product; it does not automatically extend to semaglutide. The same cell-based assays have also been applied to biosimilar insulin¹⁴. The prudent reading is that methods exist to measure the risk, not that the risk disappears.

How to tell a generic from an unregulated product

On June 19, 2024 WHO issued Medical Product Alert N°2/2024 on falsified Ozempic: three batches detected in Brazil and the United Kingdom (October 2023) and the United States (December 2023) that reached the regulated supply chain. One had a batch number the manufacturer does not recognize; another a batch-and-serial combination matching no genuine manufacturing record; and the third a genuine batch number with falsified product⁴. The lesson is that a batch number alone is not enough: it has to be confirmable with the manufacturer or the registration holder.

• Traceability: an approved generic has a registration holder, an identifiable manufacturer and a verifiable batch; a "similar" usually has none¹⁴.
• Analytical document: a useful certificate of analysis shows HPLC purity, identity by mass spectrometry and the method; see how to read a certificate of analysis.
• Impurities: for a peptide, total purity does not replace the individual impurity profile; the topic is covered in compounded GLP-1: impurities and antibodies⁹¹².
• Presentation: a generic pen or vial inherits the safety information of the reference product, including the boxed warning².

What is still unknown

The July 2026 FDA guidances are drafts: the agency will weigh comments before finalizing them¹. Nor did the literature reviewed for this article include independent head-to-head clinical studies comparing a generic semaglutide with the reference product on hard outcomes; what exists is analytical, in vitro immunogenicity and bioequivalence data that depend on each application. Any impurity figure for a specific generic semaglutide should come from that product's dossier, not from a general article.